Merck & Co., Inc.
MRKMerck & Co., Inc. (MRK) is a global healthcare company specializing in pharmaceuticals, vaccines, and biologic therapies. Founded in 1891, it is known for developing innovative medicines across various therapeutic areas including oncology, infectious diseases, cardiology, and immunology. Merck focuses on research and development to improve health outcomes worldwide.
Dividend History
Investors can expect a dividend payout of $0.85 per share, scheduled to be distributed in 2 days on January 8, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 8, 2026 | $0.85 | 2025-12-15 | 2025-12-15 |
| October 7, 2025 | $0.81 | 2025-09-15 | 2025-09-15 |
| July 8, 2025 | $0.81 | 2025-06-16 | 2025-06-16 |
| April 7, 2025 | $0.81 | 2025-03-17 | 2025-03-17 |
| January 8, 2025 | $0.81 | 2024-12-16 | 2024-12-16 |
Dividends Summary
- Merck & Co., Inc. has issued 89 dividend payments over the past 22 years
- The most recent dividend was paid 91 days ago, on October 7, 2025
- The highest dividend payed out to investors during this period was $0.85 per share
- The average dividend paid during this period was $0.50 per share.
Company News
The pharmaceutical sector is experiencing rapid innovation in GLP-1 drugs, with Eli Lilly currently leading the market. Novo Nordisk's recent approval of a GLP-1 pill could shift dynamics again. The article recommends considering discounted shares of Bristol Myers Squibb, Merck, and Pfizer, which are currently out of favor but have proven track r...
Merck & Co. has decided not to exercise its option for Evaxion's gonorrhea vaccine candidate EVX-B2 (protein-based version), allowing Evaxion to retain global rights and seek alternative licensing partners. The decision does not impact Evaxion's cash runway extending to mid-2027. Evaxion continues developing an mRNA version with Afrigen Biologics...
Over 30 pharmaceutical companies are developing BTK inhibitors targeting B-cell cancers, autoimmune disorders, and neurological conditions, with promising pipeline drugs in various clinical trial stages.
Healthcare stocks are experiencing a sector rotation as investors move away from tech, with three large-cap pharmaceutical companies showing strong potential due to attractive valuations, breakthrough drugs, and promising earnings.
Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.
